NEWS
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
Immix Biopharma (NASDAQ: IMMX) has expanded its U.S. clinical trial sites for the NEXICART-2 study, evaluating CAR-T NXC-201 in relapsed/refractory AL Amyloidosis patients. New sites include Cleveland Clinic, UC Davis, and Sutter Health, joining lead site Memorial Sloan Kettering Cancer Center. This expansion aims to increase patient access and enrollment opportunities across the U.S.
The study builds on positive data from the ex-U.S. NEXICART-1 trial, which showed a 92% overall response rate in relapsed/refractory AL Amyloidosis patients. NXC-201 is currently the only CAR-T therapy in development for AL Amyloidosis. The expansion supports upcoming interim and final read-outs of NEXICART-2, as Immix Biopharma continues its mission to advance treatment options for this patient population.
The study builds on positive data from the ex-U.S. NEXICART-1 trial, which showed a 92% overall response rate in relapsed/refractory AL Amyloidosis patients. NXC-201 is currently the only CAR-T therapy in development for AL Amyloidosis. The expansion supports upcoming interim and final read-outs of NEXICART-2, as Immix Biopharma continues its mission to advance treatment options for this patient population.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1633Followers
89Following
12KVisitors
Follow